GlassScriptPhysician profile
Nathan C Pulkingham
NPI 1588663447
$1,006.08
in general payments reported to CMS, 2019-2025
19 companies · $158 in 2025
The $158 reported for 2025 was more than what 76% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $346 · 2022: $109 · 2023: $35.28 · 2024: $234 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $216.81 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 | |
| Boston Scientific Corporation | $100.00 | 2021 | |
| Gilead Sciences, INC. | $81.88 | 2020 | |
| Janssen Biotech, INC. | $72.52 | 2020-2024 | Rybrevant, Darzalex, Imbruvica |
| Adaptive Biotechnologies Corporation | $54.79 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $29.55 | 2025 | Datroway |
| Pharmaessentia USA Corporation | $29.17 | 2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $24.32 | 2025 | Imfinzi |
| Geron Corporation | $20.63 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.00 | 2024 | Ninlaro |
| Genentech USA, INC. | $19.42 | 2024 | Gazyva, Venclexta |
| Axonics, INC. | $16.50 | 2023 | Axonics |
| Pharmacosmos Therapeutics INC. | $16.35 | 2024 | Monoferric |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $14.90 | 2020 | |
| Beigene USA, INC. | $14.81 | 2024 | Brukinsa |
| Abbott Laboratories | $12.79 | 2022 | |
| Merck Sharp & Dohme LLC | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Pulkingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.